For more than two decades, men with prostate cancer have faced a difficult bargain: accept treatments that reliably control the disease but frequently leave lasting harm, or forgo treatment altogether. A ten-year NHS trial of nearly 3,500 men has now closed that gap, demonstrating that focal therapy — which targets only cancerous tissue rather than the whole gland — matches surgery and radiotherapy in cancer control while cutting the risk of incontinence and sexual dysfunction by more than half. The evidence arrives at a moment when regulators, policymakers, and patients are all asking the sam
Focal therapy cuts prostate cancer side effects without sacrificing survival
Thousands of men currently experience preventable side effects like incontinence and sexual dysfunction from traditional prostate cancer treatments when less harmful alternatives exist.
It feels pretty unfair that this isn't offered to men across the whole country.
Mark
Why has a treatment that's been around for over twenty years remained so marginal?
Mimi
The honest answer is fear of the unknown. Regulators and doctors worried that if you only treated part of the prostate, cancer would come back in the bits you left alone. Without long-term data, that worry seemed reasonable. But this ten-year study shows it doesn't happen.
Mark
So the evidence was always missing, not the treatment itself?
Mimi
Exactly. Focal therapy worked in smaller studies, but nobody had followed thousands of men for a decade to prove it held up. NICE wouldn't approve it without that proof, and hospitals won't offer what isn't approved. It became a catch-22.
Mark
What changes if NICE approves it now?
Mimi
Everything, potentially. Right now only ten centres in England offer it. If it becomes routine, hospitals across the country would be expected to provide it. Men wouldn't have to live in London to access it.
Mark
You mentioned the side effects are the real story here. Why does that matter so much?
Mimi
Because incontinence and sexual dysfunction aren't minor inconveniences—they're life-altering. They're why men delay diagnosis, why screening programmes haven't worked. If you can offer the same cancer control without those consequences, you change what men are willing to accept.
Mark
Does this study prove focal therapy is better, or just equal?
Mimi
Equal in terms of survival and cancer control. But better in every other way that matters to living—fewer side effects, less invasive, faster recovery. For most men, that's the whole point.
Mark
What's the barrier now?
Mimi
Mainly inertia and regulation. The evidence exists. The money is being allocated. It's about whether the system moves fast enough to make it available before more men suffer unnecessary harm.
Il Polso
- Thousands of men each year undergo treatments that leave them incontinent or sexually dysfunctional when a less harmful alternative — proven over a decade — already exists.
- Access to focal therapy is confined to just ten NHS centres in England, meaning geography, not medicine, determines whether a man is offered the option.
- The ten-year trial has dismantled the central clinical fear — that treating only part of the prostate would allow cancer to escape — with only two deaths recorded among nearly 3,500 participants.
- Government funding of £2.8 million and a £60 million screening trial called Transform signal early institutional movement, but routine access still awaits a formal NICE decision.
- Patient advocates and cancer charities argue the new data must now change not just policy documents but the conversations happening in consulting rooms across the country today.
For more than two decades, men with prostate cancer have faced a difficult bargain: accept treatments that reliably control the disease but frequently leave lasting harm, or forgo treatment altogether. A ten-year NHS trial of nearly 3,500 men has now closed that gap, demonstrating that focal therapy — which targets only cancerous tissue rather than the whole gland — matches surgery and radiotherapy in cancer control while cutting the risk of incontinence and sexual dysfunction by more than half. The evidence arrives at a moment when regulators, policymakers, and patients are all asking the same question: if a gentler path leads to the same destination, why are so few men being shown it?
A decade-long NHS study has produced the evidence that prostate cancer specialists had long been waiting for: focal therapy, which destroys only cancerous tissue using ultrasound or extreme cold rather than removing or irradiating the entire prostate, controls the disease just as effectively as surgery or radiotherapy — but with less than half the rate of serious side effects. Led by Imperial College London and published in European Urology, the trial followed nearly 3,500 men with intermediate or high-risk prostate cancer over ten years. Only two died from the disease. Incontinence and sexual dysfunction, the consequences that make men dread a prostate cancer diagnosis, were dramatically reduced.
Despite being available for more than twenty years, focal therapy reaches only around 1,000 men annually on the NHS, in a country where up to 15,000 could benefit. The treatment is offered at just ten centres in England and nowhere else in the UK. The barrier has been regulatory: without long-term survival data, NICE has not approved focal therapy as routine care, and hospitals have not been required to provide it. The new study directly addresses that gap.
For men like Rob Huxford, diagnosed at 44, access came down to living in London. His outcomes were excellent and he remains free of long-term complications — but he is candid about the inequity. Paul Sayer, who founded the charity Prost8 UK after his own experience with focal therapy, called the research a turning point that should reshape clinical conversations nationwide.
The stakes extend beyond individual treatment decisions. Prostate cancer is the most common cancer in British men, with over 64,000 diagnoses and around 12,000 deaths each year. The severity of traditional treatment side effects has long been cited as a reason why mass screening programmes are difficult to justify. A less harmful treatment pathway could change that calculus entirely.
The government has begun to respond, committing £2.8 million to expand focal therapy centres in England and funding the Transform screening trial, which offers focal therapy to all participants. High-profile disclosures from figures including Sir Chris Hoy and Jeremy Clarkson have brought the treatment into public view. Whether that momentum translates into routine nationwide access now rests with NICE and the NHS's willingness to build the infrastructure the evidence demands.
A decade-long study of nearly 3,500 men has delivered what prostate cancer specialists have been waiting for: proof that a gentler way to treat the disease works just as well as the standard approaches, and with far fewer of the consequences that make men dread the diagnosis in the first place.
The treatment is called focal therapy. Instead of removing the entire prostate or blasting it with radiation—interventions that often leave men incontinent or sexually dysfunctional—focal therapy uses either high-intensity ultrasound or extreme cold to destroy only the cancerous tissue itself, leaving the rest of the gland intact. The NHS trial, led by Imperial College London and published in the journal European Urology, followed men with intermediate or high-risk prostate cancer over ten years. The results were stark: only two of the nearly 3,500 men died from the disease. The cancer control matched what surgeons and radiotherapists achieve, but with less than half the rate of side effects.
Yet despite being introduced more than two decades ago, focal therapy remains a postcode lottery in Britain. Only about 1,000 men a year receive it on the NHS—in a country where up to 15,000 could benefit. Access is confined to ten centres in England, with none elsewhere in the UK. The reason is bureaucratic: the health regulator NICE has not approved focal therapy as routine treatment, largely because long-term survival data did not exist. Without that approval, hospitals are not required to offer it, and most do not.
Rob Huxford, diagnosed at 44 in 2020, was one of the fortunate ones. His doctor in London offered him focal therapy. "My outcomes have been fantastic," he says. "I have no long-term issues at all." But he is acutely aware of the accident of geography. "It feels pretty unfair that this isn't offered to men across the whole country. It was the fact that I live in London that I was offered that treatment." Paul Sayer, a 70-year-old who founded the charity Prost8 UK and also received focal therapy, sees the new evidence as a turning point. "This research shouldn't just change clinical practice," he told the BBC. "It should change conversations in every consulting room across the UK."
The reason focal therapy has been held at arm's length is understandable but, the data now suggests, unfounded. Regulators and clinicians worried that treating only part of the prostate might allow cancer to recur in the untreated portions, or that men might die at higher rates than those who had their entire gland removed or irradiated. The ten-year study demolishes those concerns. The outcomes are equivalent to traditional surgery and radiotherapy—but with the added benefit of preserving continence and sexual function in the vast majority of men.
The implications ripple outward. Prostate cancer is the most common cancer in men in the UK; more than 64,000 are diagnosed each year, and about 12,000 die from it. The side effects of standard treatment—incontinence, erectile dysfunction—are so severe that they have become a barrier to screening. If men knew a less harmful option existed, screening programmes might finally become feasible. Amy Rylance from Prostate Cancer UK put it plainly: "Side effects like incontinence or sexual problems can be devastating, and this is the first long-term study that shows many men could avoid them without increasing the risk their cancer could return."
The government has already begun to move. Last month it committed up to £2.8 million to expand focal therapy provision in England, creating several new centres. A £60 million screening trial called Transform is underway, offering focal therapy to all men diagnosed with prostate cancer as part of the study. High-profile figures—Olympic cyclist Sir Chris Hoy, former Prime Minister Lord Cameron, TV presenter Jeremy Clarkson—have publicly disclosed their prostate cancer diagnoses and, in some cases, their use of focal therapy, lending the treatment visibility it previously lacked.
What happens next depends on whether NICE reviews its position in light of this evidence, and whether the NHS can build the infrastructure to offer focal therapy widely. The study has handed regulators and policymakers the data they said they needed. The question now is whether they will act on it.
Citazioni salienti
Focal therapy delivers excellent long-term cancer control across a broad range of patients. It makes a compelling case for more centres to offer this treatment.— Professor Hashim Ahmed, Imperial College London
This research shouldn't just change clinical practice—it should change conversations in every consulting room across the UK.— Paul Sayer, founder of Prost8 UK
Vuoi la storia completa?
Leggi l'originale su BBC News ↗
Health & Medicine